XML 71 R26.htm IDEA: XBRL DOCUMENT v2.4.0.6
Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2011
Summary of Significant Accounting Policies [Abstract]  
Inventory Disclosure [Text Block]

 

2011

2010

Finished products

$    786.4

$   800.8

Work in process

   1,518.2

  1,714.2

Raw materials and supplies

      205.8

     220.8

 

   2,510.4

  2,735.8

Reduction to LIFO cost

    (210.6)

    (218.1)

Inventories

$2,299.8

$2,517.7

Property, Plant and Equipment Disclosure [Text Block]

 

2011

2010

Land

$   202.5

$    207.8

Buildings

   6,135.7

6,029.3

Equipment

   7,219.9

7,355.7

Construction in progress

   1,036.0

893.8

 

14,594.1

14,486.6

Less accumulated depreciation

(6,833.8)

(6,545.9)

Property and equipment, net

$7,760.3

$7,940.7

Revenue from External Customers by Products and Services [Table Text Block]

 

2011

2010

2009

 

 

 

 

Net product sales

$23,604.8

$22,442.2

$21,171.5

Collaboration and other revenue (Note 4)

       681.7

       633.8

       664.5

Total revenue

$24,286.5

$23,076.0

$21,836.0

Other - Net, Expense (Income) [Text Block]

Note 17: OtherNet, Expense:

Othernet, expense consisted of the following:

 

 

2011

2010

2009

 

 

Interest expense

$186.0

$185.5

$261.3

Interest income

(79.9)

(51.9)

(75.2)

Other (income) expense

72.9

(128.6)

43.4

Othernet, expense

$179.0

$    5.0

$229.5

 

Other expense for the year ended December 31, 2011 primarily consists of the partial impairment on acquired IPR&D assets related to liprotamase and Amyvid (Note 7) partially offset by gains on the disposal of investment securities. For the year ended December 31, 2010, other (income) expense primarily consists of damages recovered from generic pharmaceutical companies related to Zyprexa patent litigation in Germany and gains on the disposal of investment securities.